Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Aldesleukin may stimulate lymphocytes to kill melanoma cells. Treating lymphocytes
with interleukin-21 in the laboratory may help the lymphocytes kill more tumor cells when
they are put back in the body. Giving therapeutic autologous lymphocytes together with
cyclophosphamide and aldesleukin may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of giving therapeutic
autologous lymphocytes together with cyclophosphamide and aldesleukin in treating patients
with metastatic melanoma